The money will support the development of the firm's PidPort system for storage, viewing, sharing, and analysis of digital images of pathology slides.

The firm filed for Chapter 11 protection on Thursday and is seeking to sell its assets after facing turmoil in recent years.

April's clearances included respiratory disease assays, a Gram-negative infection test, and assays to aid the diagnosis and monitoring of thyroid disease.

The company has received a commitment of up to $12.5 million in a multi-draw DIP financing facility to provide funding during the proceeding.

NEW YORK — Exagen, a developer of autoimmune testing technologies, said on Thursday it expects to raise around $17.6 million through a public offering of its common stock.